Clinical manifestations, treatment options, and comorbidities in COVID‐19 relapse patients: A systematic review

Abstract

Introduction Interest revolving around coronavirus disease 2019 (COVID‐19) reinfection is escalating rapidly. By definition, reinfection denotes severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), PCR redetection, and COVID‐19 recurrence within three months of the initial symptoms. The main aim of the current systematic review was to evaluate the features of COVID‐19 relapse patients. Materials and methods For this study, we used a string of terms developed by a skilled librarian and through a systematical search in PubMed, Web of Science, and Embase for eligible studies. Clinical surveys of any type were included from January 2019 to March 2021. Eligible studies consisted of two positive assessments separated by a negative result via RT‐PCR. Results Fifty‐four studies included 207 cases of COVID‐19 reinfection. Children were less likely to have COVID‐19 relapse. However, the most patients were in the age group of 20–40 years. Asthenia (66.6%), headache (66.6%), and cough (54.7%) were prevalent symptoms in the first SARS‐CoV‐2 infection. Asthenia (62.9%), myalgia (62.9%), and headache (61.1%) were most frequent in the second one. The most common treatment options used in first COVID‐19 infection were lopinavir/ritonavir (80%), oxygen support (69.2%), and oseltamivir (66.6). However, for the treatment of second infection, mostly antibiotics (100%), dexamethasone (100%), and remdesivir (80%) were used. In addition, obesity (32.5%), kidney failure (30.7%), and hypertension (30.1%) were the most common comorbidities. Unfortunately, approximately 4.5% of patients died. Conclusion We found the potency of COVID‐19 recurrence as an outstanding issue. This feature should be regarded in the COVID‐19 management. Furthermore, the first and second COVID‐19 are similar in clinical features. For clinically practical comparison of the symptoms severity between two epochs of infection, uniform data of both are required. We suggest that future studies undertake a homogenous approach to establish the clinical patterns of the reinfection phenomena.

Evaluating the characteristics of patients with SARS-CoV-2 infection admitted during COVID-19 peaks: A single-center study

“…The infection is transmitted by droplet (direct inhalation of droplets from the sneeze, cough, or talking of an infected person) or contact (contacting the virus deposited on an object surface, which then enters the body via the mouth, nose, eyes, or other mucous membrane [ 10 , 11 ]. The clinical characteristics for COVID-19 appear 1–14 days after infection, and most patients develop symptoms within 3–7 days [ 12 , 13 ]. Fever, cough, and dyspnea were the most common symptoms in patients with COVID-19 pneumonia [ 14 , 15 ], followed by the manifestation of lower respiratory tract infections [ 16 ].…”

Milder outcomes of SARS-CoV-2 genetically confirmed reinfections compared to primary infections with the delta variant: A retrospective case-control study

“…However, we also observed a significantly higher proportion of reported sore throat in the case group (30% vs. 24% in the control group) and a significantly higher proportion of headache in the case group (31% vs. 25% in the control group). The complex interplay of immune system response, virus characteristics, and the social conduct of the individuals makes the characterization of symptomatic profiles difficult ( 32 ). To address this issue would require a more focused study to further elucidate the factors that contribute to a specific symptom profile in each group.…”

A Comprehensive Review of the Protein Subunit Vaccines Against COVID-19

“…The world has been fighting coronavirus disease 2019 (COVID-19) illness for nearly 2 years ( Koupaei et al, 2022a ; Naimi et al, 2022 ). COVID-19 was induced by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), which emerged in Wuhan, China ( Koupaei et al, 2021 ; Mahdizade Ari et al, 2022 ).…”